Cargando…
Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe α1-antitrypsin deficiency
BACKGROUND: Individuals with severe Z α1-antitrypsin (AAT) deficiency have a considerably increased risk of developing chronic obstructive lung disease (COPD). It has been hypothesized that compensatory increases in levels of other protease inhibitors mitigate the effects of this AAT deficiency. We...
Autores principales: | Hollander, Camilla, Westin, Ulla, Wallmark, Anders, Piitulainen, Eeva, Sveger, Tomas, Janciauskiene, Sabina M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800898/ https://www.ncbi.nlm.nih.gov/pubmed/17261175 http://dx.doi.org/10.1186/1471-2466-7-1 |
Ejemplares similares
-
Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals
por: Sandström, Caroline S, et al.
Publicado: (2008) -
Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine release
por: Nita, Izabela, et al.
Publicado: (2005) -
Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases
Publicado: (1988) -
Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019) -
Circulating monocytes from healthy individuals and COPD patients
por: Aldonyte, Ruta, et al.
Publicado: (2003)